Adaptive Biotechnologies (ADPT) Change in Accured Expenses (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Change in Accured Expenses data on file, last reported at -$7.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 22.28% year-over-year to -$7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 155.77% YoY) and the FY2025 annual result came in at $665000.0, down 0.89% from the prior year.
• Change in Accured Expenses declined to -$7.5 million in Q1 2026 per ADPT's latest filing, from $1.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $10.5 million in Q4 2022, with the low at -$15.9 million in Q1 2023.
• Average Change in Accured Expenses over 5 years is -$263058.8, with a median of $407000.0 recorded in 2024.
• Year-over-year, Change in Accured Expenses slumped 150.71% in 2023 and jumped 10093.22% in 2025.
• Adaptive Biotechnologies' Change in Accured Expenses stood at $10.5 million in 2022, then plunged by 49.3% to $5.3 million in 2023, then fell by 20.13% to $4.3 million in 2024, then tumbled by 72.68% to $1.2 million in 2025, then slumped by 744.81% to -$7.5 million in 2026.
• Business Quant data shows ADPT's Change in Accured Expenses at -$7.5 million in Q1 2026, $1.2 million in Q4 2025, and $5.9 million in Q3 2025.